EN DE
STOCK COMPARISON

Alteogen vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Alteogen (196170) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 14, 2026.

As of Aug 14, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alteogen trades at KRW 314,000 versus a fair value of KRW 39,476 (-87%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).
Alteogen
196170.KQ · KRW · Health Care
-87%
upside to fair value
overvalued
PriceKRW 314,000
Fair ValueKRW 39,476
Quality70/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-46%
upside to fair value
overvalued
Price$516
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AlteogenVertex Pharmaceuticals
Valuation
P/E (TTM)28.8×
0.05×P/S (TTM)10.06×
P/B6.59×
EV/EBITDA23.8×
PEG1.72×
0.1%Dividend yield
KRW 371Dividend per share
Profitability
64%Net margin36%
55%Operating margin38%
25%Return on equity24%
8%Return on assets12%
Growth
-15%Revenue growth (YoY)8%
95.7%Avg. growth/yr (3Y)10.6%
38.5%Avg. growth/yr (5Y)14.2%
Balance & size
0.01×Debt / equity0.03×
$10BMarket cap$123B
healthyGrowth qualityhealthy

Alteogen leads: 7 to 2 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Alteogenof which business quality 71 · market factors 20 Vertex Pharmaceuticalsof which business quality 77 · market factors 73
ProfitabilityMargins and returns on capital today
71
72
Quality GrowthAre margins and returns improving?
95
65
CashflowEarnings quality: real cash, not paper profit
72
79
Fin. StrengthBalance sheet, leverage, solvency risk
86
92
InvestmentDisciplined investing over empire-building
8
58
Low VolatilityCalm price path (market factor)
33
86
MomentumPrice trend over the last 3–12 months (market factor)
17
60
52W MomentumDistance to the 52-week high (market factor)
10
80
Net IssuanceBuybacks instead of dilution
74
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Alteogen

DCF ModelsKRW 54,926
Earnings-BasedKRW 92,661
MultiplesKRW 32,849
Asset-BasedKRW 5,574
Growth DCFKRW 44,371
Economic ProfitKRW 36,157
Growth EarningsKRW 123,001

24 of 24 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

21 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Alteogen
Bear KRW 24,681Fair Value KRW 39,476Bull KRW 51,158
KRW 314,000 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$516 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Alteogen · Health Care

Quality score70 · Top 25%
Fair value upside-87% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-46% · below median

Bottom line

As of Aug 14, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alteogen trades at KRW 314,000 versus a fair value of KRW 39,476 (-87%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.